Dmitry Balyasny’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$39.6M Buy
+678,741
New +$40M 0.05% 477
2025
Q4
– Sell
-27,511
Closed -$971K – 3488
2025
Q3
$971K Buy
+27,511
New +$996K ﹤0.01% 2124
2025
Q1
– Sell
-59,755
Closed -$1.52M – 3218
2024
Q4
$1.52M Buy
+59,755
New +$1.58M ﹤0.01% 1770
2024
Q1
– Sell
-95,382
Closed -$2.68M – 3050
2023
Q4
$2.68M Buy
95,382
+27,445
+40% +$754K 0.01% 1357
2023
Q3
$1.84M Buy
+67,937
New +$2.02M ﹤0.01% 1395
2022
Q4
– Sell
-285,034
Closed -$11.5M – 3173
2022
Q3
$11.5M Buy
+285,034
New +$12.2M 0.04% 625
2022
Q2
– Sell
-197,889
Closed -$7.71M – 3112
2022
Q1
$7.71M Buy
+197,889
New +$7.77M 0.02% 788

Other funds holding RPRX

Dmitry Balyasny's RPRX Position: Q3 2026 in Review

Dmitry Balyasny opened a new position in Royalty Pharma (RPRX) in Q3 2026: 678,741 shares worth $39.6M. The stake represents 0.05% of the portfolio and ranks #477 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in RPRX as recently as Q3 2025.

Dmitry Balyasny first reported a position in RPRX in Q1 2022 and has held it in 7 quarters since. 695 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Dmitry Balyasny held 678,741 shares of Royalty Pharma worth $39.6M as of Q3 2026.
  • Royalty Pharma was a new Dmitry Balyasny position in Q3 2026.
  • Royalty Pharma made up 0.05% of Dmitry Balyasny's portfolio in Q3 2026, its #477 holding.
  • Dmitry Balyasny first reported a position in Royalty Pharma in Q1 2022 and has held it in 7 quarters since.
  • 695 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.